Follow-up strategies following completion of primary cancer treatment in adult cancer survivors
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most cancer survivors receive follow-up care after completion of treatment with the primary aim of detecting recurrence. Traditional follow-up consisting of fixed visits to a cancer specialist for examinations and tests are expensive and may be burdensome for the patient. Follow-up strategies involving non-specialist care providers, different intensity of procedures, or addition of survivorship care packages have been developed and tested, however their effectiveness remains unclear. OBJECTIVES: The objective of this review is to compare the effect of different follow-up strategies in adult cancer survivors, following completion of primary cancer treatment, on the primary outcomes of overall survival and time to detection of recurrence. Secondary outcomes are health-related quality of life, anxiety (including fear of recurrence), depression and cost. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, four other databases and two trials registries on 11 December 2018 together with reference checking, citation searching and contact with study authors to identify additional studies. SELECTION CRITERIA: We included all randomised trials comparing different follow-up strategies for adult cancer survivors following completion of curatively-intended primary cancer treatment, which included at least one of the outcomes listed above. We compared the effectiveness of: 1) non-specialist-led follow-up (i.e. general practitioner (GP)-led, nurse-led, patient-initiated or shared care) versus specialist-led follow-up; 2) less intensive versus more intensive follow-up (based on clinical visits, examinations and diagnostic procedures) and 3) follow-up integrating additional care components relevant for detection of recurrence (e.g. patient symptom education or monitoring, or survivorship care plans) versus usual care. DATA COLLECTION AND ANALYSIS: We used the standard methodological guidelines by Cochrane and Cochrane Effective Practice and Organisation of Care (EPOC). We assessed the certainty of the evidence using the GRADE approach. For each comparison, we present synthesised findings for overall survival and time to detection of recurrence as hazard ratios (HR) and for health-related quality of life, anxiety and depression as mean differences (MD), with 95% confidence intervals (CI). When meta-analysis was not possible, we reported the results from individual studies. For survival and recurrence, we used meta-regression analysis where possible to investigate whether the effects varied with regards to cancer site, publication year and study quality. MAIN RESULTS: We included 53 trials involving 20,832 participants across 12 cancer sites and 15 countries, mainly in Europe, North America and Australia. All the studies were carried out in either a hospital or general practice setting. Seventeen studies compared non-specialist-led follow-up with specialist-led follow-up, 24 studies compared intensity of follow-up and 12 studies compared patient symptom education or monitoring, or survivorship care plans with usual care. Risk of bias was generally low or unclear in most of the studies, with a higher risk of bias in the smaller trials. Non-specialist-led follow-up compared with specialist-led follow-up It is uncertain how this strategy affects overall survival (HR 1.21, 95% CI 0.68 to 2.15; 2 studies; 603 participants), time to detection of recurrence (4 studies, 1691 participants) or cost (8 studies, 1756 participants) because the certainty of the evidence is very low. Non-specialist- versus specialist-led follow up may make little or no difference to health-related quality of life at 12 months (MD 1.06, 95% CI -1.83 to 3.95; 4 studies; 605 participants; low-certainty evidence); and probably makes little or no difference to anxiety at 12 months (MD -0.03, 95% CI -0.73 to 0.67; 5 studies; 1266 participants; moderate-certainty evidence). We are more certain that it has little or no effect on depression at 12 months (MD 0.03, 95% CI -0.35 to 0.42; 5 studies; 1266 participants; high-certainty evidence). Less intensive follow-up compared with more intensive follow-up Less intensive versus more intensive follow-up may make little or no difference to overall survival (HR 1.05, 95% CI 0.96 to 1.14; 13 studies; 10,726 participants; low-certainty evidence) and probably increases time to detection of recurrence (HR 0.85, 95% CI 0.79 to 0.92; 12 studies; 11,276 participants; moderate-certainty evidence). Meta-regression analysis showed little or no difference in the intervention effects by cancer site, publication year or study quality. It is uncertain whether this strategy has an effect on health-related quality of life (3 studies, 2742 participants), anxiety (1 study, 180 participants) or cost (6 studies, 1412 participants) because the certainty of evidence is very low. None of the studies reported on depression. Follow-up strategies integrating additional patient symptom education or monitoring, or survivorship care plan
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
ROBIS: A new tool to assess risk of bias in systematic reviews was developed
Whiting, P., Savović, J., Higgins, J. P. T., Caldwell, D. M., Reeves, B. C., Shea, B., Davies, P., Kleijnen, J., & Churchill, R. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.06.005 · Cited by 2,272
Simard, S., & Savard, J. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-008-0444-y · Cited by 608
Puhan, M. A., Frey, M., Büchi, S., & Schünemann, H. J. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-46 · Cited by 586
Models for Delivering Survivorship Care
Oeffinger, K. C., & McCabe, M. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0474 · Cited by 485
Follow-up strategies for patients treated for non-metastatic colorectal cancer
Jeffery, M., Hickey, B. E., & Hider, P. N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002200.pub2 · Cited by 205
Howell, D., Hack, T. F., Oliver, T. K., Chulak, T., Mayo, S., Aubin, M., Chasen, M., Earle, C. C., Friedman, A. J., Green, E., et al. (2012) · Journal of Cancer Survivorship · doi:10.1007/s11764-012-0232-z · Cited by 156
Using technology to deliver cancer follow-up: a systematic review
Dickinson, R., Hall, S., Sinclair, J. E., Bond, C., & Murchie, P. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-311 · Cited by 146
Nicolaije, K. A. H., Ezendam, N. P. M., Vos, M. C., Pijnenborg, J. M. A., Boll, D., Boss, E. A., Hermans, R. H. M., Engelhart, K. C. M., Haartsen, J. E., Pijlman, B. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.3399 · Cited by 112
for the FUPII Trial Investigators, Boekhout, A. H., Maunsell, E., Pond, G. R., Julian, J. A., Coyle, D., Levine, M. N., & Grunfeld, E. (2015) · Journal of Cancer Survivorship · doi:10.1007/s11764-015-0443-1 · Cited by 88
Maly, R. C., Liang, L.-J., Liu, Y., Griggs, J. J., & Ganz, P. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.9497 · Cited by 69
Kimman, M. L., Dirksen, C. D., Voogd, A. C., Falger, P., Gijsen, B. C. M., Thuring, M., Lenssen, A., van der Ent, F., Verkeyn, J., Haekens, C., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.12.017 · Cited by 66
Meulen, I. C., May, A. M., Ros, W. J. G., Oosterom, M., Hordijk, G.-J., Koole, R., & Leeuw, J. R. J. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0299 · Cited by 45
Cited by
Improved models of care for cancer survivors
Jefford, M., Howell, D., Li, Q., Lisy, K., Maher, J., Alfano, C. M., Rynderman, M., & Emery, J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00306-3 · Cited by 281
Vaz-Luis, I., Masiero, M., Cavaletti, G., Cervantes, A., Chlebowski, R. T., Curigliano, G., Felip, E., Ferreira, A. R., Ganz, P. A., Hegarty, J., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.1941 · Cited by 208
Self-citationChan, R. J., Crawford-Williams, F., Crichton, M., Joseph, R., Hart, N. H., Milley, K., Druce, P., Zhang, J., Jefford, M., Lisy, K., et al. (2023) · Journal of Cancer Survivorship · doi:10.1007/s11764-021-01128-1 · Cited by 192
Metadata
- Authors
- Høeg, B. L., Bidstrup, P. E., Karlsen, R. V., Friberg, A. S., Albieri, V., Dalton, S. O., Saltbaek, L., Andersen, K. K., Horsboel, T. A., & Johansen, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2019-11-21
- Volume
- 2019
- Issue
- 11
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2555016775
- Cited by
- 114
- References
- 16
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.